Q1 2022 Results

Company overview Financial review 2022 priorities Appendix References 3 INNOVATION NATALEE: Latest event rate forecast indicates readout now in 2023, as event rate lower than originally projected CEZ KISQALI K L NATALEE study design HR+/HER2- eBC RIB+ ET R Pre- and post- menopausal 1:1 Anatomic Stage II & III N=5000 ET Ribociclib 400mg/day 3 weeks on/1 week off 36 months (~39 cycles) 36 months 60 months NSAI 60 months [+goserelin in pre-menopausal women & men] NSAI 60 months 60 months [+ goserelin in pre-menopausal women & men] eBC - early breast cancer 1. Projections based on data up to 03-Mar-2022. As of 20-Apr-2022, 303 events have been documented. 19 Investor Relations | Q1 2022 Results ☐ ☐ Recruitment completed to 5,000 patients, including intermediate and high risk (Apr 2021) Primary analysis planned at 500 iDFS events; ~300 events to date Successfully completed futility analysis in Q1 2022 Two interim analyses for efficacy planned; none has occurred yet ■ Discontinuation rate remains low NOVARTIS | Reimagining Medicine

View entire presentation